DNA damage repair inhibitors for treatment of cancer
AssigneesKudos Pharmaceuticals Limited, The Institute of Cancer Research
InventorsAlan Ashworth, Stephen Jackson, Niall Martin, Graeme Smith, Mark O'Connor
Life of this patent
Estimating the term…
Abstract
DNA Damage Repair Inhibitors for Treatment of Cancer The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Claims26
A method of treatment of cancer in an individual comprising;
- administering an inhibitor of a BER pathway to said individual,
- wherein said cancer is deficient in a HR dependent DNA DSB repair pathway.
A method of treating cancer comprising administering an inhibitor of HR dependent DNA DSB repair and an inhibitor of base excision repair to an individual in need thereof.
Dependencies are inferred from the claim text.